Oric Pharmaceuticals, Inc. Common Stock
ORICOric Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted therapies for cancer, with an emphasis on overcoming resistance to existing treatments. Founded with the goal of advancing precision medicine, Oric aims to address unmet needs in oncology by developing novel agents that improve patient outcomes.
Company News
Pomerantz LLP is investigating potential securities fraud claims against ORIC Pharmaceuticals following a 41% stock price decline on March 31, 2026. The drop occurred after the company announced that its prostate cancer treatment (rinzimetostat/ORIC-944) performed roughly as effectively as competitors, falling short of expectations that it would ...
ORIC Pharmaceuticals announced equity inducement grants of 80,000 non-qualified stock options and 15,000 restricted stock units to a new non-executive employee hired in March 2026. The grants were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4) and vest over time based on continued employment.
ORIC Pharmaceuticals (NASDAQ: ORIC) surged 3.94% during regular trading but plummeted 24.86% in after-hours trading despite releasing positive Phase 1b clinical data for its lead drug candidate rinzimetostat in combination with darolutamide for metastatic castration-resistant prostate cancer. The treatment showed an 84% radiographic progression-f...
The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep...
ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, demonstrating strong systemic and CNS activity in NSCLC patients with EGFR exon 20 mutations, with high objective response rates and a competitive safety profile.
